A Phase I/II Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer.

Trial Profile

A Phase I/II Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Monoclonal antibody F16 I 131 (Primary)
  • Indications Breast cancer; Cancer; Colorectal cancer; Lung cancer; Lymphoma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Philogen
  • Most Recent Events

    • 24 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Nov 2011 Planned end date changed from 1 Oct 2012 to 1 Feb 2012 as reported by ClinicalTrials.gov.
    • 24 Aug 2011 Planned End Date changed from 1 Jul 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top